How to buy Arcturus Therapeutics stock | $29.22

Arcturus Therapeutics Holdings Inc is a biotechnology business based in the US. Arcturus Therapeutics shares (ARCT) are listed on the NASDAQ and all prices are listed in US Dollars. Arcturus Therapeutics employs 118 staff and has a trailing 12-month revenue of around 0.00.

Arcturus Therapeutics stock price (NASDAQ: ARCT)

Use our graph to track the performance of ARCT stocks over time.

Arcturus Therapeutics shares at a glance

• Key figures

Information last updated 2021-07-28.

Latest market close	$29.22
52-week range	$24.87 - $129.71
50-day moving average	$32.71
200-day moving average	$44.17
Wall St. target price	$80.36
PE ratio	N/A
Dividend yield	N/A (0%)
Earnings per share (TTM)	$-1.26

Buy Arcturus Therapeutics shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.

*Signup bonus information updated weekly.

Is it a good time to buy Arcturus Therapeutics stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

Technical Analysis of Arcturus Therapeutics Holdings Inc by TradingView

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Arcturus Therapeutics price performance over time

Historical closes compared with the close of $29.22 from 2021-05-28

1 week (2021-07-23)	N/A
1 month (2021-07-02)	-15.87%
3 months (2021-05-03)	-18.79%
6 months (2021-01-30)	N/A

1 year (2020-07-30)	N/A
2 years (2019-07-30)	N/A
3 years (2018-07-30)	N/A
5 years (2016-07-30)	N/A

Arcturus Therapeutics financials

Revenue TTM	$9 million
Gross profit TTM	$-48,307,000
Return on assets TTM	-27.04%
Return on equity TTM	-64.24%
Profit margin	0%
Book value	$13.40
Market capitalisation	$870.1 million

TTM: trailing 12 months

Shorting Arcturus Therapeutics shares

There are currently 3.7 million Arcturus Therapeutics shares held short by investors – that's known as Arcturus Therapeutics's "short interest". This figure is 6.6% down from 4.0 million last month.

There are a few different ways that this level of interest in shorting Arcturus Therapeutics shares can be evaluated.

Arcturus Therapeutics's "short interest ratio" (SIR)

Arcturus Therapeutics's "short interest ratio" (SIR) is the quantity of Arcturus Therapeutics shares currently shorted divided by the average quantity of Arcturus Therapeutics shares traded daily (recently around 544415.86608443). Arcturus Therapeutics's SIR currently stands at 6.87. In other words for every 100,000 Arcturus Therapeutics shares traded daily on the market, roughly 6870 shares are currently held short.

However Arcturus Therapeutics's short interest can also be evaluated against the total number of Arcturus Therapeutics shares, or, against the total number of tradable Arcturus Therapeutics shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Arcturus Therapeutics's short interest could be expressed as 0.14% of the outstanding shares (for every 100,000 Arcturus Therapeutics shares in existence, roughly 140 shares are currently held short) or 0.1732% of the tradable shares (for every 100,000 tradable Arcturus Therapeutics shares, roughly 173 shares are currently held short).

A SIR below 10% would generally be considered to indicate a fairly optimistic outlook for the share price, with fewer people currently willing to bet against Arcturus Therapeutics.

Find out more about how you can short Arcturus Therapeutics stock.

Arcturus Therapeutics share dividends

We're not expecting Arcturus Therapeutics to pay a dividend over the next 12 months.

Have Arcturus Therapeutics's shares ever split?

Arcturus Therapeutics's shares were split on a 1:7 basis on 15 November 2017. So if you had owned 7 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your Arcturus Therapeutics shares – just the quantity. However, indirectly, the new 600% higher share price could have impacted the market appetite for Arcturus Therapeutics shares which in turn could have impacted Arcturus Therapeutics's share price.

Arcturus Therapeutics share price volatility

Over the last 12 months, Arcturus Therapeutics's shares have ranged in value from as little as $24.87 up to $129.71. A popular way to gauge a stock's volatility is its "beta".

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Arcturus Therapeutics's is 2.7124. This would suggest that Arcturus Therapeutics's shares are significantly more volatile than the average for this exchange and represent a higher risk.

Arcturus Therapeutics overview

Arcturus Therapeutics Holdings Inc. , an RNA medicines company, focuses on the treatment of liver and respiratory care diseases. Its preclinical drug discovery and development programs include LUNAR-OTC development program for ornithine transcarbamylase (OTC) deficiency; and LUNAR-CF program for cystic fibrosis lung disease caused by mutations in cystic fibrosis transmembrane conductance regulator (CFTR) gene. The company owns LUNAR and nucleic acid technologies that are covered by a patent portfolio of 209 patents and patent applications, issued in the United States and other countries. It has collaboration partnerships with Ultragenyx Pharmaceutical, Inc. to develop mRNA therapeutic candidates for certain rare disease targets; Millennium Pharmaceuticals, Inc. (Takeda) to develop a nucleic acid-based therapeutic candidate for the treatment of nonalcoholic steatohepatitis; Janssen Pharmaceuticals, Inc.

Frequently asked questions

What percentage of Arcturus Therapeutics is owned by insiders or institutions?
Currently 17.952% of Arcturus Therapeutics shares are held by insiders and 73.923% by institutions. How many people work for Arcturus Therapeutics?
Latest data suggests 118 work at Arcturus Therapeutics. When does the fiscal year end for Arcturus Therapeutics?
Arcturus Therapeutics's fiscal year ends in December. Where is Arcturus Therapeutics based?
Arcturus Therapeutics's address is: 10628 Science Center Drive, San Diego, CA, United States, 92121 What is Arcturus Therapeutics's ISIN number?
Arcturus Therapeutics's international securities identification number is: US03969T1097 What is Arcturus Therapeutics's CUSIP number?
Arcturus Therapeutics's Committee on Uniform Securities Identification Procedures number is: 03969T109